Brief: Brainstorm Cell Therapeutics To Meet With US FDA To Discuss Development Plan For NurOwn As A Treatment Of ALS

Brainstorm Cell Therapeutics

18/10/2023 11:38

Oct 18 (Reuters) - Brainstorm Cell Therapeutics Inc
 BCLI.O :
    * BRAINSTORM CELL THERAPEUTICS TO MEET WITH US FDA TO
DISCUSS
DEVELOPMENT PLAN FOR NUROWN AS A TREATMENT OF ALS
    * BRAINSTORM CELL THERAPEUTICS INC - PATH FORWARD FOR ALS IS
A
REGISTRATIONAL PHASE 3B U.S. CLINICAL TRIAL
    * BRAINSTORM CELL THERAPEUTICS INC - BIOLOGICS LICENSE
APPLICATION
TO BE WITHDRAWN WITHOUT PREJUDICE
    * BRAINSTORM CELL THERAPEUTICS INC: BIOLOGICS LICENSE
APPLICATION
TO BE WITHDRAWN WITHOUT PREJUDICE
    * BRAINSTORM CELL THERAPEUTICS INC - REMAINS COMMITTED TO
ALS
COMMUNITY AND IS ACTIVELY EXPLORING NEXT STEPS IN SUPPORT OF
NUROWN
    * BRAINSTORM CELL THERAPEUTICS INC - DECISION TO WITHDRAW
BLA WAS
COORDINATED WITH FDA AND IS VIEWED BY FDA AS A WITHDRAWAL
WITHOUT PREJUDICE

Source text for Eikon:  ID:nPn4vBfwGa 
Further company coverage:  BCLI.O 

 ((reuters.briefs@thomsonreuters.com;))